Loading clinical trials...
Loading clinical trials...
The purpose of this study is to evaluate the effect and safety of orforglipron once daily in participants with Fontaine II peripheral arterial disease (PAD). Participation in the study will last about...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
CONTACT
317-615-4559LillyTrials@Lilly.comPhysicians interested in becoming principal investigators please contact
CONTACT
clinical_inquiry_hub@lilly.comLead Sponsor
Eli Lilly and Company
NCT06112171 · Peripheral Arterial Disease
NCT03663777 · Peripheral Arterial Disease
NCT07223437 · Peripheral Arterial Disease
NCT07497360 · Peripheral Arterial Disease
NCT04584632 · Peripheral Arterial Disease, Vascular Diseases, and more
St. Vincent's Birmingham Hospital
Birmingham, Alabama
Mercy Gilbert Medical Center
Gilbert, Arizona
Emvera Health at Peak Heart & Vascular Surprise
Surprise, Arizona
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions